Nucleic Acids Encoding Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 14/234,021, filed Feb 26, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,856,325 | Nucleic Acids Encoding Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence UsedRemaining | CSL Behring GmbH | In force | High confidence | ||
| US 9,856,326 | Methods of Administering Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Behring GmbH | In force | High confidence | ||
| US 10,513,560 | Methods of Administering Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Ltd. | In force | High confidence | ||
| US 9,518,127 | Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies and Their Uses In force · High confidence | CSL Ltd. | In force | High confidence | ||
| US 11,345,759 | Methods of Administering Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies In force · High confidence | CSL Ltd. | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by CSL Behring GmbH.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.